• Ming-Lung Yu, Pei-Jer Chen, Chia-Yen Dai, Tsung-Hui Hu, Chung-Feng Huang, Yi-Hsiang Huang, Chao-Hung Hung, Chun-Yen Lin, Chen-Hua Liu, Chun-Jen Liu, Cheng-Yuan Peng, Han-Chieh Lin, Jia-Horng Kao, and Wan-Long Chuang.
• Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; School of Medicine and Hepatitis Research Center, College of Medicine, Center for Cancer Research and Center for Liquid Biopsy, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: fish6069@gmail.com.
• J Formos Med Assoc. 2020 Jun 1; 119 (6): 1019-1040.

AbstractHepatitis C virus (HCV) infection remains a major public health issue with high prevalence in Taiwan. Recently, the advent of direct-acting antiviral (DAA) agents, with higher efficacy, excellent safety profile, and truncated treatment duration, has revolutionized the paradigm of hepatitis C treatment and made HCV elimination possible. To provide timely guidance for optimal hepatitis C management, the Taiwan Association for the Study of the Liver (TASL) established an expert panel to publish a 2-part consensus statement on the management of hepatitis C in the DAA era. After comprehensive literature review and a consensus meeting, patient-oriented, genotype-guided recommendations on hepatitis C treatment for the general and special populations have been provided based on the latest indications and scientific evidence. In the first part of this consensus, we present the epidemiology and treatment situation of hepatitis C in Taiwan, the development of DAA, pre-treatment evaluation, post sustained virologic response (SVR) monitoring, and most importantly the treatment recommendations for the general population with compensated liver disease. The second part will focus on the treatment recommendations for the special populations.Copyright © 2020 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

17 keywords...

hide…